India, May 31 -- Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT) given for six months before and after prostate cancer surgery. The investigational regimen significantly improved both short- and long-term outcomes for patients with high-risk localized or locally advanced disease.
The trial met both primary endpoints. Patients treated with apalutamide plus hormone therapy were nine times more likely to have little to no cancer remaining at surgery compared with hormone therapy alone (8.9% vs. 1.0%). The combination also reduced the risk of metastasis or death by 20% and extended the time before patients required su...